Related Experiment Video

Updated: Oct 5, 2026

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

C-reactive protein in patients with familial hypercholesterolemia: no effect of simvastatin therapy

M F Mohrschladt1, M P de Maat, R G Westendorp

  • 1Department of General Internal Medicine, Leiden University Medical Center, PO Box 9600, 2300 RC Leiden, The Netherlands.

Atherosclerosis
|July 27, 2001
PubMed

Insights

C-reactive protein (CRP) is linked to cardiovascular disease (CVD) in familial hypercholesterolemia (FH) patients. One year of simvastatin treatment did not significantly alter CRP levels in this high-risk group.

Area of Science:

  • Biochemistry
  • Cardiology
  • Pharmacology

Background:

  • Familial hypercholesterolemia (FH) patients face elevated risks of premature cardiovascular disease (CVD).
  • C-reactive protein (CRP) is a key predictor of future CVD events, indicating its role in atherosclerosis.
  • Understanding CRP dynamics in FH is crucial for managing cardiovascular risk.

Purpose of the Study:

  • To assess the impact of one-year simvastatin treatment on serum CRP levels in FH patients.
  • To investigate the association between CVD risk factors and CRP concentrations in FH.
  • To determine if simvastatin therapy influences CRP levels in FH patients.

Main Methods:

  • Baseline CRP levels measured in 337 FH patients.
  • Subgroup analysis of 129 patients after one year of simvastatin (20-40 mg/day) treatment.
  • Correlation analysis of CRP with CVD risk factors including smoking, BMI, age, triglycerides, and medication use.

Main Results:

  • FH patients with existing CVD had significantly higher baseline CRP levels (2.26 mg/l vs. 1.55 mg/l).
  • CRP levels correlated with smoking, body mass index, age, triglyceride levels, and use of NSAIDs or anticoagulants.
  • Simvastatin improved lipid profiles but did not significantly decrease CRP levels (median decrease from 1.51 to 1.24 mg/l, P=0.328).

Conclusions:

  • Elevated CRP levels are associated with the presence of CVD in familial hypercholesterolemia patients.
  • Simvastatin therapy, while improving lipid profiles, demonstrated no significant effect on CRP levels in this cohort.
  • Further research may explore other interventions targeting CRP in FH for CVD risk reduction.

More Related Videos

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein07:29

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...